Introduction
Conditionally replicative adenoviruses (CRAds) represent a novel class of anticancer agents designed to selectively replicate in tumor cells and to destroy these cells by inducing lysis. 1, 2 The current generation of CRAds is derived from human adenovirus serotype 5 (Ad5), for which the coxsackievirus and adenovirus receptor (CAR) has been identified as a high-affinity receptor. 3, 4 Unfortunately, several primary human cancers express low levels of CAR and are refractory to adenovirus infection. [5] [6] [7] [8] [9] [10] In particular, high-grade undifferentiated tumors exhibited decreased CAR expression. 11, 12 Furthermore, primary tumors revealed heterogeneous CAR expression, sometimes with a focal distribution pattern. 6, 11 Thus, lack of CAR expression in primary tumors or tumor regions may hinder CRAdbased therapies. Recently, it was confirmed that CAR deficiency on tumor cells indeed limits the oncolytic potency of a replicating adenovirus. 13 A rational approach to improve the efficacy of CRAds as anticancer agents could be to enhance their infection efficiency on CAR-deficient tumor cells by redirecting viral entry via a CAR-independent pathway. This should augment the infection efficiency during replication and lateral spread in a CAR-deficient or heterogeneous tumor.
Currently, two general strategies are being considered to redirect the entry pathway of adenoviruses in order to enhance their infectivity and specificity. In the first strategy, the adenovirus genome is modified to alter the binding specificity of the viral capsid. 14 In the second strategy, a two-component targeted adenovirus is constructed by coupling proteins with specific binding affinity onto the viral capsid. [5] [6] [7] [15] [16] [17] [18] [19] In the context of CRAds, the first approach appears most appropriate because the targeting specificity is made inherent to the viral genome and thus maintained upon replication. Utility of this strategy was recently confirmed by oncolytic replication of an adenovirus with a chimeric Ad3/Ad5 fiber protein to target infection via the putative Ad3 receptor in renal cell carcinoma models resistant to Ad5 infection. 20 Although useful to demonstrate the benefit of targeting, application of such pseudotyped adenoviruses is limited by the targeting repertoire of naturally occurring adenovirus serotypes. As an alternative, CRAd tropism was expanded through incorporation of defined targeting peptides in the Ad5 fiber knob. These infectivity-enhanced CRAds showed improved oncolytic potency on cancer cells in vitro and in vivo. 21, 22 Thus, the potential of targeted CRAds for the treatment of cancer is clearly established. A major obstacle for wider application of fiber-modified CRAds with other recognition specificities is, however, that the adenovirus fiber appears to impose not yet fully understood structural demands on the incorporated ligand. [23] [24] [25] The repertoire of genetically targeted CRAds could potentially be expanded tremendously if more complex, highaffinity ligands such as antibodies could be used. However, such molecules have so far not been successfully incorporated as a stable component of the adenovirus capsid. In addition, the nuclear assembly of adenoviruses may preclude correct post-translational modification of protein moieties that are normally processed through the secretory pathway. For these reasons, complex binding ligands including antibodies have so far only been successfully employed in twocomponent targeting strategies, where they were bound to the adenovirus fiber indirectly via a second protein moiety. [5] [6] [7] [15] [16] [17] [18] However, in the currently available twocomponent systems, the targeting moiety is not part of the CRAd genome and is thus lost upon viral replication. A two-component targeted CRAd administered to a CAR-deficient tumor may, therefore, at best benefit from an enhanced infection by the initial viral inoculum. The more important advantage of in situ replication and lateral spread in the tumor would still be hampered by CAR deficiency of the target cells. To provide a solution for this limitation, we constructed a new type of targeted CRAd that carries an expression cassette for a secreted antibody targeting moiety in its genome. The targeting moiety is the bispecific single-chain (scFv) antibody 425-S11 consisting of the anti-epidermal growth factor receptor (EGFR) scFv 425 and anti-adenovirus fiber knob scFv S11 that targets adenovirus entry via EGFR. 17, 26 In contrast to CAR, EGFR is commonly overexpressed in many tumor types. 27 Here, we show that the novel EGFR-targeted CRAd produced its own bispecific scFvtargeting moiety, while replicating in CAR-deficient cancer cells, providing its progeny with CAR-independent infectivity. As a result, the EGFR-targeted CRAd exhibited improved oncolytic potency on CAR-deficient cancer cells, primary brain tumor specimens, and 3-D tumor spheroids in vitro. Hence, the new CRAd presented herein combines the therapeutic gains of targeting and oncolytic replication, in a stable singlecomponent genetic anticancer medicine, with the flexibility of a two-component targeting strategy.
Results

EGFR-targeted bispecific scFv augments adenovirus replication on CAR-deficient cancer cells
For the first series of experiments, we used the replication-competent adenovirus AdE1 þ Luc that expresses the firefly luciferase gene. Virus replication was monitored by luciferase activity measurement on two human glioma cell lines with different CAR-expression levels, that is, CAR-positive U373MG cells and CAR-deficient U118MG cells (Figure 1a) . The first few days postinfection, U118MG cells exhibited approximately 10 times lower luciferase expression levels than U373MG cells, which probably reflected a difference in infection efficiency of the virus inoculum. During the course of in vitro replication, the difference in luciferase expression between the two cell lines increased to approximately 4 logs. This suggested that, as expected, replication was severely hampered in CAR-deficient cells, which was further corroborated by an approximately 3-log higher virus titer measured on U373MG cells than on U118MG cells after 12 days culture (Figure 1b) . To test the hypothesis that an EGFR-targeted bispecific scFv would enhance adenovirus propagation on U118MG cells by providing CAR-independent entry, we infected U118MG cultures with AdE1 þ Luc in the presence of 425-S11 bispecific scFv. 17 Over the 14-day period, U118MG cultures in medium containing 425-S11 produced approximately 2-log higher luciferase readings and 85-fold more virus than cultures without 425-S11 ( Figure 1 ). These observations prompted us to explore the utility of 425-S11-targeted replication-competent adenoviruses for the treatment of CAR-deficient tumors. We constructed Ad425S11, a replication-defective adenovirus vector (AdV) expressing green fluorescent protein (GFP) and 425-S11. CAR-deficient, EGFR-positive U118MG cells were infected with a dual-virus mixture consisting of AdE1 þ Luc and Ad425S11, or with a control mixture of AdE1 þ Luc and AdGFP and cultured for 1 week during which 425-S11 secretion and virus release were monitored. In the culture medium of AdE1 þ Luc/Ad425S11-infected cells, 425-S11 bispecific scFv could be detected as early as 1 day after infection (Figure 2a) . The concentration of 425-S11 in the medium peaked at days 2 and 3 when cells experienced a cytopathic effect (CPE), after which it gradually declined. The lysis of cells due to viral replication resulted in the release of newly formed virus into the culture medium after approximately 3 days (Figure 2b ). Most importantly, cells infected with AdE1 þ Luc/Ad425S11 produced progeny virus capable of infecting CAR-deficient U118MG cells (Figure 2c ). In contrast, virus released from cells infected with AdE1 þ Luc/AdGFP showed hardly any infectivity on U118MG cells. Thus, during adenovirus replication, AdE1 þ Luc/Ad425S11-infected cells secreted bispecific scFv 425-S11 that provided released progeny virus with CAR-independent infectivity.
EGFR-targeted bispecific scFv enhance spread and oncolysis by replication-competent adenovirus on CAR-deficient cancer cells
To investigate if the enhancement of adenovirus infectivity due to 425-S11 secretion would lead to a more efficient spread in a population of CAR-deficient tumor cells, we tested the efficacy of virus progeny from AdE1 þ Luc/Ad425S11-infected U118MG cells to further propagate on U118MG cells. At 5 days after infection, cell-free culture medium containing released virus progeny was harvested and used to infect a monolayer of freshly seeded U118MG cells. This procedure was repeated for three cycles of reinfection. After each infection, cell viability, luciferase expression, 425-S11 secretion, and EGFR-targeted virus titer were determined ( Figure 3 ). Propagation of control AdE1 þ Luc/ AdGFP virus resulted in rather low levels of luciferase expression in the cells, indicative of hampered replication ( Figure 3a ) and release of virus with low CARindependent infectivity (Figure 3b) . Consequently, the oncolytic potential of the virus was completely lost within two rounds of reinfection (Figure 3c ). In contrast, the virus released from AdE1 þ Luc/Ad425S11-infected cells exhibited approximately 100-fold increased infectivity on U118MG cells (Figure 3b ), leading to efficient replication in each next monolayer of infected U118MG cells, as indicated by the constant high levels of luciferase 
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VW van Beusechem et al expression after each cycle of reinfection ( Figure 3a ). Most importantly, the enhanced infectivity allowed the replicating virus to retain its oncolytic capacity upon propagation. After three rounds of reinfection, CARdeficient U118MG cells were still killed very efficiently ( Figure 3c ). However, the concentration of secreted 425-S11 declined with each cycle of infection ( Figure 3d ). This coincided with a loss of GFP expression in the cells (not shown). Apparently, in the dual-virus infection strategy where the AdV is rendered replicative through transcomplementation of E1 proteins, the AdE1 þ Luc virus had a replication advantage over the Ad425S11 vector. We concluded, therefore, that while dual-virus infections were useful to test the concept of targeting CRAds, they have limited utility to develop improved cancer therapies.
EGFR-targeted CRAd exhibits enhanced replication on cancer cells with low or absent CAR expression
Based on the encouraging results obtained with dualvirus mixtures, we constructed the EGFR-targeted CRAd AdD24-425S11 by inserting an expression cassette for 425-S11 into the genome of AdD24DE3 that encodes pRbbinding deficient E1A proteins. 28, 29 AdD24-425S11-infected cells secreted 425-S11 into the culture medium (confirmed by ELISA, not shown). EGFR-positive human cancer cell lines differing in CAR expression (see Figure  4 ) were infected with purified AdD24DE3 or AdD24-425S11 virus at various multiplicities of infection (MOIs). Subsequently, CRAds were allowed to replicate for 2 weeks, after which monolayer cytolysis was examined by crystal violet staining ( Figure 4 ). In this assay, the infection by both CRAd inoculums is CAR-dependent. However, during propagation when AdD24-425S11 produces the 425-S11-targeting adapter protein differences in lytic replication rate of the progeny viruses may be revealed. Following 2 weeks propagation, AdD24DE3 and AdD24-425S11 had lysed cancer cells with high CAR expression (HT29 and HeLa shown in Figure 4 ; A549, NCI-H460, U373MG, and HepG2 not shown) with similar efficiency. These cells were completely eradicated after infection at an MOI of 0.1-1 plaque-forming units (PFU)/cell. In contrast, AdD24DE3 killed CAR-deficient U118MG and T24 cells only at an MOI above 100 PFU/ cell, while CAR-low A431 and MDA-MB-231 cells were killed with intermediate efficiency. Most importantly, EGFR-targeted AdD24-425S11 exhibited 10-1000-fold greater oncolytic potency than AdD24DE3 on these CAR-deficient and CAR-low cancer cells. Hence, the EGFR-targeted CRAd overcame resistance to oncolysis due to lack of adenovirus receptor expression on cancer cells.
EGFR-targeted CRAd exhibits enhanced replication on primary human malignant glioma cells
Since primary high-grade malignant gliomas are often CAR-deficient but EGFR-positive, 5, 6, 26 we evaluated the utility of AdD24-425S11 in this context. Eight glioblastoma multiforme (GBM) specimens were obtained from patients undergoing surgery and short-term cultures were established. FACS analysis for CAR revealed that five samples were CAR-deficient with relative median fluorescence (RMF) values ranging from 1.0 to 1.2, two were CAR-low (RMF 1.7 and 2.1), and one was CARhigh (RMF 6.2). Samples were infected with AdD24DE3 or AdD24-425S11 at low MOIs and cultured for up to 25 days. WST-1 cell viability measurement showed that AdD24DE3 killed the CAR-high specimen VU-78 effectively, with only 7% cell survival after 12 days replication ( Figure 5c ) and less than 1% survival after 14 days (not AdD24-425S11 exhibits enhanced oncolytic potency on primary human GBM specimens. Five CAR-deficient GBM specimens (a), two CAR-low specimens (b), and one CAR-high specimen (c) were subjected to infection with AdD24DE3 or AdD24-425S11 at 1 PFU/cell and cultured for 12 days (VU-78), 14 days (VU-95), 18 days (VU-94) or 25 days (all CAR-deficient specimens). Cell viability was measured by WST-1 conversion assay and is given as per cent survival compared to uninfected control cultures. Data are means þ s.d. of triplicate measurements.
Targeting CRAd towards EGFR VW van Beusechem et al shown). AdD24DE3 had, however, no or little efficacy against most CAR-deficient and CAR-low samples. Even after prolonged incubation, AdD24DE3-infected specimens did not show significant decrease in viability compared to noninfected controls (Figure 5a,b) . In contrast, AdD24-425S11 was effective against the CARhigh, one of the two CAR-low and all five CAR-deficient GBM specimens. Its efficacy against CAR-low and CARdeficient specimens was significantly enhanced compared to its parental control AdD24DE3 (Po0.01). Sample VU-94 that survived AdD24DE3 as well as AdD24-425S11 infection was killed very efficiently by AdD24-p53, 29 indicating that the refractoriness of this glioma to CRAd replication was due to hampered cell death rather than CAR deficiency (VWB, unpublished results). In conclusion, EGFR targeting enhanced the efficacy of AdD24DE3 treatment on six out of eight tested GBM specimens.
EGFR-targeted CRAd exhibits enhanced lateral spread in tumor spheroids
To investigate the importance of targeting for lateral spread of a CRAd in a 3-D solid tumor, we established CAR-deficient multicellular T24 bladder cancer spheroids containing 1 or 10% CRAd-infected cells. After 2 weeks culture, cell viability was quantified by WST-1 conversion measurement and adenovirus replication was visualized by immunocytochemistry. The viability of T24 spheroids established with 1% infected cells was not significantly affected (not shown). In contrast, as can be seen in Figure 6a , 10% AdD24-425S11 infection caused significant cell death compared to noninfected controls (53%, Po0.001), whereas AdD24DE3 infection did not decrease spheroid viability. Thus, EGFR targeting augmented CRAd-induced oncolysis in CAR-deficient tumor nodules in vitro. Sections of T24 spheroids made with 1% infected cells were stained with an antiadenovirus antibody (Figure 6b ). Cells containing replicating adenovirus were detected in all CRAd-infected spheroids. In AdD24DE3-infected spheroids, CRAd replication was mainly confined to individual cells dispersed through the spheroid, with only one out of eight analyzed spheroids exhibiting connected areas of CRAd-positive cells. In contrast, all but one AdD24-425S11-infected spheroids contained connected areas of replicating virus, confirming that enhanced cytotoxicity of AdD24-425S11 was related to enhanced lateral spread.
Discussion
The anticancer efficacy of CRAds depends on their efficiency to infect tumor cells, to selectively replicate in these cells, to release progeny virus by inducing oncolysis, and to spread to neighboring tumor cells. One important restriction to CRAd oncolytic potency is lack of CAR expression on cancer cells. 13 Therefore, redirecting CRAd entry via CAR-independent pathways may increase the therapeutic utility of CRAds. Previously, we have shown that the bispecific scFv 425-S11, which targets adenoviruses towards the EGFR, enhances transduction of CAR-deficient cancer cells with AdV. 6, 7, 17, 26 Here, we investigated if EGFR targeting using 425-S11 could also enhance the oncolytic potency of a CRAd. To provide the CRAd with constant EGFRtargeting properties during replication, 425-S11 was produced from a stable expression cassette inserted into the CRAd genome.
Initially, we performed experiments on CAR-deficient U118MG glioma cells using dual-virus mixtures consisting of a replication-competent virus expressing a marker gene and an AdV secreting 425-S11. These investigations confirmed the utility of secreted EGFR-targeting antibodies to enhance cytotoxicity of a replicating adenovirus on a CAR-deficient cancer cell population. Importantly, because the targeting antibodies were secreted by the cells in which the adenovirus was replicating, these studies also showed that adenovirus replication did not inhibit 425-S11 production or vice versa. However, we also observed that the replicationcompetent virus had a replication advantage over the replication-deficient AdV. This is to be expected in situations where the infection efficiency is below 100%. The replication-competent virus will replicate in every cell it has infected, while the AdV will only produce progeny in the subset of cells infected with both viruses. Since in vivo adenovirus administration will often result We chose AdD24DE3 as a backbone to construct an EGFR-targeted CRAd. AdD24DE3 encodes E1A proteins with a deletion of eight amino acids in the pRb-binding CR2 domain that confers selective replication in cells with dysfunctional pRb control. 28 It has already been shown that infection with D24-type CRAds effectively kills cancer cells in vitro and inhibits tumor growth in vivo, while replication is reduced in nonproliferating normal cells and in cancer cells with restored pRb function. 28, 31 Although proliferating normal cells were not entirely resistant to D24-type CRAd replication, 31, 32 strict pRb selectivity was obtained by introducing additional regulatory elements in this CRAd backbone. 32 Thus, CRAds with the D24 mutation are relevant contexts in which to test the utility of infectivity enhancement. Notably, however, the targeting strategy investigated here can be applied to any kind of CRAd, irrespective of the genome modification conferring selective replication.
We made the EGFR-targeted AdD24DE3-derivative virus AdD24-425S11 by inserting a 425-S11 expression cassette into the AdD24DE3 genome. The 425 moiety of 425-S11 has been described to display EGFR-antagonistic properties. 33, 34 Therefore, it was conceivable that 425-S11 would suppress cell-cycle progression in AdD24-425S11-infected cancer cells through inhibition of EGFR signaling. Since AdD24DE3 replication requires dysfunctional cell-cycle regulation, 425-S11 could potentially inhibit AdD24-425S11 replication and oncolysis. We have, however, not observed delayed replication of AdD24-425S11 compared to AdD24DE3 (data not shown). In any event, we considered targeting cancer cells via a growth factor receptor antagonist preferred over strategies using active mitogenic ligands. 15, 16 In fact, secretion of an EGFR-antagonistic targeting antibody might be considered an additional anticancer attribute of the new CRAd.
AdD24-425S11 killed CAR-deficient cancer cells at 1-3-log lower viral titer than did AdD24DE3 with native tropism. Importantly, enhanced oncolysis by EGFR targeting was also observed on most short-term cultured high-grade malignant glioma samples, suggesting utility of the new CRAd for the treatment of brain tumors. Cells in these and other tumors often lack CAR expression and are therefore poorly infected by adenoviruses. [5] [6] [7] [8] [9] [10] [11] [12] In fact, this notion was the major incentive to develop new CRAds with CAR-independent infectivity. Previously, two types of CRAds with defined CAR-independent tropism were reported, that is, an E1B-55K-deleted Ad5 with a stretch of lysine residues added to the carboxyterminus of the fiber protein 21 and an Ad5-D24 variant with a cyclic RGD peptide insertion in the fiber HI loop (Ad5-D24RGD). 22 The oncolytic potency of these CRAds was initially evaluated only on cancer cell lines with high CAR expression. Hence, their utility in the context of cells that require targeting was not demonstrated. Recently, Ad5-D24RGD was compared to Ad5-D24 on CAR-deficient rhabdomyosarcoma RD cells and on RD cells stably transfected to express CAR. 10 CAR-deficient as well as CAR-expressing RD cells were killed only by Ad5-D24RGD, confirming enhanced oncolytic capacity of Ad5-D24RGD compared to Ad5-D24, and suggesting that this involved other differences between the two viruses than infectivity-enhancement alone. In this regard, it is noteworthy that Ad5-D24RGD contains an intact E3 region while Ad5-D24 is E3-deleted, a difference recently confirmed to have major impact on the Ad5-D24 oncolytic potency. 35 . In the present study, we compared AdD24DE3 and AdD24-425S11, which have identical E1A-mutant E3-deleted genomes except for the inserted 425-S11 expression cassette, and found that AdD24-425S11 killed CAR-deficient and CAR-low cancer cells much more effectively than did AdD24DE3. Hence, our findings are consistent with the notion that infectivity enhancement leads to more effective oncolysis of cancers with low or absent CAR.
We also investigated the lateral spread of AdD24-425S11 in an in vitro model for solid tumors, where diffusion of large molecules, such as viruses, is hampered by the tumor structure and the composition of the tumor extracellular matrix. We applied multicellular tumor spheroids, in which cells are held together by surface membrane microprojections, extracellular matrix, and a variety of cell-cell junctions. 36 Previously, we have shown that AdV do not penetrate into spheroids, but that replication-competent viruses can spread in these structures layer-by-layer. 37 Indeed, AdD24DE3 replicated in CAR-positive spheroids causing progressive cell death (not shown), but this process was severely hampered in CAR-deficient T24 spheroids. In contrast, AdD24-425S11 killed T24 spheroids more effectively and exhibited larger areas of viral replication in these structures, suggesting that EGFR targeting may also augment CRAd oncolytic potency on solid tumors.
In conclusion, we have shown that CRAds expressing their own targeting adapter molecule are promising agents for the treatment of CAR-deficient cancers. Importantly, the bispecific scFv construct that we used allows simple exchange of the EGFR-targeting moiety for an scFv with alternative specificity. For example, AdV targeted towards the epithelial cell adhesion molecule were already made in this way and shown to provide efficient and selective transduction of cancer cells. 26, 38 Thus, this versatile targeting approach allows tailored construction of CRAds with binding affinity for other molecules expressed on cancer cells using analogous procedures. In addition, the S11 moiety of the bispecific scFv binds not only to native adenovirus fiber knobs, but also to knobs that were made CAR-binding deficient by specific amino-acid deletions. 26, 39 Selective transduction of cancer cells using bispecific scFv together with AdV deficient in CAR and/or integrin binding was already demonstrated. 26, 38 Hence, the strategy described herein, where a bispecific scFv targeting-antibody is expressed from the CRAd genome, could perhaps be combined with mutations in the CRAd genome that abolish CAR 
Materials and methods
Cells and culture conditions
Adenovirus E1-complementing 293 cells, SV40 T-complementing COS-7 cells, A431 squamous skin carcinoma cells, A549 and NCI-H460 lung carcinoma cells, MDA-MB-231 breast carcinoma cells, HeLa cervix carcinoma cells, HepG2 hepatoma cells, U373MG astrocytoma cells, and HT-29 colon carcinoma cells were all obtained from the ATCC (Manassas, VA, USA); U118MG glioma cells and T24 bladder cancer cells were kindly provided by Dr JT Douglas (Gene Therapy Center, UAB, Birmingham, AL, USA) and Dr HG van der Poel (Department of Urology, NKI, Amsterdam, Netherlands), respectively. NCI-H460 cells were maintained in RPMI1640 with 10% FCS and antibiotics; all other cell lines were maintained in F12-supplemented DMEM with 10% FCS and antibiotics (all from Gibco BRL Life Technologies, Paisley, UK). All tissue culture plastic materials were from Greiner Bio-One GmbH (Frickenhausen, Germany).
Fresh tumor material was collected during brain tumor surgery of consenting patients at the Departments of Neurosurgery of the VU University Medical Center and the Academic Medical Center (Amsterdam, the Netherlands), and processed within 3 h after dissection. Pathologic confirmation of the diagnosis was made on the tumor material that was processed for cell culture. All samples included in the study were characterized as GBM. Primary GBM cells were obtained after mechanical dissociation of tumor resection material and cultured in DMEM supplemented with 10% FCS and antibiotics. CRAd replication and FACS experiments were done before passage 10.
FACS analysis
CAR and EGFR expression levels were analyzed after incubating cells with RmcB anti-CAR MoAb 40 or 425 anti-EGFR MoAb (culture supernatant from the 425 hybridoma cell line; ATCC), respectively, followed by RbaMIgG-FITC (DAKO, Glostrup, Denmark). Negative controls were incubated with second antibody only. Cells were analyzed on a FACScan (Beckton-Dickinson, Erembodegem-Aalst, Belgium), using CellQuest software (Beckton-Dickinson). On the basis of relative median fluorescence (RMF) signal intensity of anti-CAR MoAb stained cells compared to negative control stained cells, samples were classified as CAR deficient (RMF 1.0-1.5), CAR low (RMF 1.6-5.0), or CAR high (RMF45.0).
Recombinant adenoviruses
The replication-deficient adenovirus vector AdGFP has been described before. 41 Ad425S11 was constructed by inserting the 1.6 kb 425-S11 NheI-PmeI fragment from pSTCF-425,S11 17 into XbaI-EcoRV-digested pAdTrackCMV 42 and cotransfecting the resulting construct pAdTrackCMV-425S11 after PacI digestion together with PacI-linearized pAdEasy-1 42 into 293 cells. The resulting vector Ad425S11 has a backbone identical to AdGFP, with an additional CMV promoter-driven expression cassette encoding the bispecific single-chain fusion antibody 425-S11 with amino-terminal Igk leader and carboxy-terminal Myc-6His tag inserted into the E1 region.
AdE1 þ Luc (kindly provided by Dr R Vogels, Crucell Holland BV, Leiden, the Netherlands) is derived from wild-type Ad5 through replacement of the gp19k open reading frame in the E3 region by the firefly luciferase gene. Luciferase expression is therefore under the control of the endogenous E3 promoter.
To construct CRAds with an expression cassette for 425-S11 in place of the E3 region, the CMV-425S11 expression cassette was amplified from pSTCF-425,S11 by PCR with sense primer 5 0 -CAGCATGCTATGGTC GACTCTCAGTACAATCTGCTC-3 0 and antisense primer 5 0 -AAGCCATAGAGCCCACCGCATCC-3 0 . The 2.7 kb amplification product was digested with SphI that cuts in the sense primer sequence (underlined) and four nucleotides adjacent to the antisense primer annealing site and inserted into SphI-digested pABS.4 (Microbix Biosystems, Toronto, Canada) to create pABS.4-425S11. Functional expression of the bispecific scFv was confirmed following transient transfection of pABS.4-425S11 into COS-7 cells. At 2 days after transfection, when cells stained positive by immunocytochemistry with an antiMyc antibody, culture supernatant was harvested and found positive in a bispecific scFv ELISA (see below) and in a FACS binding assay on EGFR-expressing A431 cells, confirming S11 antiadenovirus fiber knob and 425 anti-EGFR functionality, respectively. The 4.1 kb PacI fragment from pABS.4-425S11 carrying the CMV-425S11 cassette and kanamycin resistance gene was inserted into pBHG11 (Microbix Biosystems). A clone with an insert in the orientation that places the CMV-425S11 cassette on the adenovirus R-strand was isolated and the kanamycin resistance gene was removed by digestion with SwaI followed by self-ligation, yielding pBHG11-425S11-R.
CRAds were made by homologous recombination in 293 cells between pXC1-D24 (a generous gift of Dr Ramon Alemany, Gene Therapy Center, UAB, AL, USA), a pXC1 (Microbix Biosystems) derivative carrying a 24 bp deletion in the pRb-binding CR2 domain in E1A, 28 and pBHG11 or pBHG11-425S11-R. This way, the parental control virus AdD24DE3 (previously called AdD24 29 ) and the EGFR-targeted derivative AdD24-425S11 were made. AdD24DE3 and AdD24-425S11 carry the same D24 E1A mutation 28 and have identical deleted E3 regions (Ad5 nt 27865-30995). They only differ in the CMV-425S11 cassette insertion in AdD24-425S11.
All viruses were plaque purified, propagated on 293 cells for replication-deficient vectors or on A549 cells for CRAds, and CsCl gradient purified according to standard techniques. The D24 E1 mutation and CMV-425S11 inserts were confirmed by PCR on the final products and 425-S11 secretion into the culture medium of Ad425S11 or AdD24-425S11-infected cells was detected by ELISA. Particle titers of all adenoviruses were determined by OD 260 measurement and functional PFU titers were determined by limiting dilution plaque titration on 293 cells according to standard techniques. Particle/PFU ratios were 4 for AdGFP, 26 for Ad425S11, 2 for AdE1 þ Luc, 42 for AdD24DE3, and 11 for AdD24-425S11. In all experiments, infections were normalized on the basis of PFU titers.
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Replication of AdE1 þ Luc on U118MG and U373MG cells
Cells seeded 5 Â 10 4 per well in 24-well plates were infected with AdE1 þ Luc at an MOI of 0.01 PFU/cell, with or without 10 vol% culture medium of COS-7 cells transfected with pSTCF-425,S11. Cultures were maintained for up to 14 days with addition of fresh COS-7/ 425-S11 medium to the relevant cultures on day 6. At several time points, the culture medium was harvested and cleared by centrifugation. Adherent and nonadherent cells were collected, resuspended in PBS and lysed by three freeze/thaw cycles. Luciferase activity measurement was performed on total cell lysates using the Luciferase Chemiluminescent Assay System (Promega, Madison, WI, USA) and a Lumat LB 9507 luminometer (EG&G Berthold, Bad Wildbad, Germany). Luciferase activity is given in relative light units (RLU), after subtraction of the background. In addition, on day 12 the cell-free culture medium and the cleared cell lysate were used to measure virus titers by standard limiting dilution plaque assay on 293 cells.
Replication of dual-virus mixtures on U118MG cells
Mixtures with equal PFU titers were prepared of AdE1 þ Luc with AdGFP or AdE1 þ Luc with Ad425S11. These mixtures were incubated at RT for 30 min in 425-S11-containing serum-free culture medium. Next, the virus mixtures were diluted in F12-supplemented DMEM with 2% FCS and used to infect U118MG cells at 500 PFU of both viruses per cell for 2 h at 371C. The cells were washed once with culture medium and then cultured in fresh medium at 371C for up to 7 days. At several time points, the culture medium was harvested and cleared by centrifugation. The cellfree supernatant was used to measure 425-S11 by ELISA and to determine the titers of released AdE1 þ Luc virus (see below). For propagation experiments, the cell-free culture medium of U118MG cells infected as above was harvested 5 days after infection and 25% of the volume was used to infect freshly seeded U118MG cells. Harvest of the culture medium, clearance by centrifugation, and reinfection were repeated three times with a 5-day interval. GFP expression analysis, luciferase activity measurement, 425-S11 ELISA, and virus titration were performed on day 5 after each cycle of infection. Cell viability was measured by replacing the culture medium with 200 ml 10% WST-1 (Roche Diagnostics, Mannheim, Germany) in culture medium and incubation at 371C for 1 h. Next, 100 ml medium was transferred to a 96-well ELISA plate and the OD 450 was measured. WST-1 conversion was expressed in absolute values, after subtraction of background OD 450 of WST-1 incubated in the absence of cells.
Assessment of CRAd oncolytic potency by crystal violet CPE assay
Cancer cells were seeded 5 Â 10 4 per well in 24-well plates and infected at various MOIs with AdGFP, Ad425S11, AdD24DE3, or AdD24-425S11 without adding bispecific scFv targeting molecules for 1 h at 371C. Subsequently, the cells were cultured in 1 ml medium at 371C for 2 weeks with 50% medium refreshment every 4-5 days. The culture medium was then removed and adherent cells were fixed for 10 min at room temperature with 4% formaldehyde in PBS, and subsequently stained using 1% crystal violet dye in 70% ethanol for 20 min at room temperature. After several washes with water, the culture plates were air dried and scanned on a Bio-Rad GS-690 imaging densitometer.
Replication and cytotoxicity of CRAds on primary GBM specimens
Depending on cell size, short-term GBM cell cultures were seeded 2-5 Â 10 5 cells per well to prepare subconfluent monolayers in six-well plates. The next day, the cells were infected at 1 PFU/cell with AdD24DE3 or AdD24-425S11, without adding bispecific scFv targeting molecules for 1 h at 371C. Subsequently, cells were cultured at 371C for 12-25 days depending on CAR expression level, before analysis of cell survival by WST-1 conversion assay. All cells (adherent and nonadherent) were harvested and reseeded in triplicate dilution titrations in a 96-well culture plate and cultured in 10% WST-1 for up to 16 h before OD 450 measurement. Values in the linear range were used to calculate the relative survival compared to noninfected control cells, after subtraction of the background. Statistical significance of enhanced oncolysis of CAR-deficient and CAR-low GBM specimens by AdD24-425S11 was tested by one-tailed Wilcoxon's signed-rank test using InStat software (GraphPad Software, San Diego, CA, USA).
Replication and cytotoxicity of CRAds on multicellular tumor spheroids T24 cells were infected with AdD24DE3 or AdD24-425S11 at 100 PFU/cell without adding bispecific scFv targeting molecules for 6 h at 371C. Staining with antiadenovirus fiber MoAb 4D2 (NeoMarkers, Fremont, CA, USA) at 24 h postinfection showed that the two CRAds had infected T24 cells with similar efficiency. CRAd-infected and control noninfected cell populations were mixed at 1:9 or 1:99 ratio. These mixtures or control noninfected cells were plated at a fixed number (3 Â 10 4 ) per well in 96-well plates coated with 2% multipurpose agarose (Roche Diagnostics). Spheroids were established during 16 h rotation on a horizontal platform at 115 rpm. Subsequently, spheroids were cultured at 371C, 5% CO 2 in a humidified atmosphere. After 14 days culture with 50% medium refreshment every 3-4 days, cell viability in spheroids was determined by WST-1 conversion assay. Spheroids were transferred individually to an ELISA plate and cultured in 10% WST-1 for 5 h. OD 450 was measured directly on spheroid-containing wells. Viability was expressed relative to uninfected control spheroids, after subtraction of background values of WST-1 incubated in the absence of spheroids. The statistical significance of differences between treatment groups was tested by Tukey-Kramer multiple comparisons test using Instat software (GraphPad Software). In addition, spheroids made with 1% infected cells were snap-frozen in OCT (Sakura Finetech Europe, Zoeterwoude, The Netherlands) and 8-mm sections were made. IHC staining was performed on 4% formaldehyde-fixed and 0.2% Triton X-100-treated sections, preincubated with normal rabbit serum (DAKO) diluted 1:50 in PBS/1% BSA, using polyclonal goat antiadenovirus antibody (CHEMICON International Inc., Temecula, CA, USA) diluted 1:1000 in PBS/1% BSA, followed by biotinylated rabbit anti-goat 
Bispecific scFv ELISA
ELISA 96-well plates were coated for 1 h at 371C with 20 mg/ml recombinant adenovirus fiber knob protein 43 in PBS and blocked overnight at 41C in PBS/0.05% Tween-20/0.5% BSA. Serial dilutions of harvested culture media were incubated in the wells for 2-3 h at 371C. Bound bispecific scFv were detected by OD 490 measurement after subsequent incubations with anti-myc MoAb 9E10 (supernatant from hybridoma line MYC 1-9E10.2; ATCC) for 1 h at 371C, rabbit anti-mouse IgG-HRP conjugate (DAKO) for 1 h at RT, and o-phenylenediamine substrate (DAKO) for 3 min at RT. Bispecific scFv concentrations are given in arbitrary units, calculated by multiplying the OD 490 value measured in the linear range of the serial dilution by the dilution used.
Titration of AdE1 þ Luc virus
The cleared culture supernatant was serially diluted in 
